Gregory M. M. Videtic, MD, CM
Articles by Gregory M. M. Videtic, MD, CM
This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.
ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent
ByJoe Yujiao Chang, MD, PhD,Larry L. Kestin, MD,R. Bryan Barriger, MD,Indrin J. Chetty, PhD,Mark E. Ginsburg, MD,Sanath Kumar, MD,Billy W. Loo, Jr, MD, PhD,Benjamin Movsas, MD,Andreas Rimner, MD,Kenneth E. Rosenzweig, MD,Thomas E. Stinchcombe, MD,Gregory M. M. Videtic, MD, CM,Henning Willers, MD The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.
